STRUCT/FUNCT ANALYSIS OF ANTHRACYCLINE REDUCTION BY HUMAN CARBONYL REDUCTASE

人羰基还原酶还原蒽环类化合物的结构/功能分析

• 批准号: 7381311
• 负责人: Henry Charlier
• 金额: $ 8.1万
• 依托单位: UNIVERSITY OF IDAHO
• 依托单位国家: 美国
• 财政年份: 2006
• 资助国家: 美国
• 起止时间: 2006-05-01 至 2007-04-30
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/7381311
• 关键词: STRUCT; FUNCT; ANALYSIS; ANTHRACYCLINE; REDUCTION

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. Structure/function analysis of anthracycline reduction by human carbonyl reductase Anthracyclines are a family of drugs commonly used to treat cancer. Though potent anti-tumor drugs, their use is limited due to potentially life-threatening cardiotoxicity. There is significant evidence that the toxic effects are due to an anthracycline alcohol metabolite that can form and accumulate in cardiac cells. One enzyme thought to be linked to the formation of this metabolite is carbonyl reductase (CR) This proposal seeks to define the function of CR with the long term goal of predicting the susceptibility of patients to anthracycline cardiotoxicity. The specific aims of this project are: 1) To characterize kinetically recombinant human carbonyl reductase; 2) To design and test inhibitors of recombinant human carbonyl reductase; 3) To crystallize recombinant human carbonyl reductase and determine its X-ray crystalline structure. Crystals of CR will be sent to Dr. Ramaswamy at the University of Iowa for further analysis and structure determination.

该子项目是利用NIH/NCRR资助的中心赠款提供的资源的许多研究子项目之一。子项目和研究者（PI）可能从另一个NIH来源获得了主要资金，因此可以在其他CRISP条目中表示。所列机构为中心机构，不一定为研究者机构。人羰基还原酶还原蒽环类抗生素的结构/功能分析蒽环类抗生素是一类常用于治疗癌症的药物。虽然是有效的抗肿瘤药物，但由于可能危及生命的心脏毒性，它们的使用受到限制。有重要证据表明，毒性作用是由于蒽环类醇代谢产物可在心脏细胞中形成和蓄积。一种被认为与这种代谢物的形成有关的酶是羰基还原酶（CR）。该提案旨在确定CR的功能，其长期目标是预测患者对蒽环类药物心脏毒性的敏感性。 本项目的具体目标是：1）重组人羰基还原酶的动力学表征; 2）重组人羰基还原酶抑制剂的设计和检测; 3）重组人羰基还原酶的结晶和X-射线晶体结构测定。CR的晶体将被送到爱荷华州大学的Ramaswamy博士那里进行进一步的分析和结构测定。